[
  {
    "ts": null,
    "headline": "Ametek price target raised to $215 from $205 at KeyBanc",
    "summary": "KeyBanc analyst Steve Barger raised the firm’s price target on Ametek (AME) to $215 from $205 and keeps an Overweight rating on the shares. The firm thinks Ametek has 200-400 basis points of margin expansion in its EMG segment, as the recent Paragon Medical acquisition continues to get integrated and segment margins return to mid-20s%. KeyBanc thinks 5% organic growth +3% of M&A with average incremental margins could lead to about $8.64 in EPS by FY27, implying a high single digit compound annua",
    "url": "https://finnhub.io/api/news?id=e638bc13f9ac81969c76f73ebd0db5dfc4e2a5998da6ab48841430b05c5be8ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732361432,
      "headline": "Ametek price target raised to $215 from $205 at KeyBanc",
      "id": 131587964,
      "image": "https://media.zenfs.com/en/tipranks_452/ee1bf67764e4497fe957104dc896ed25",
      "related": "AME",
      "source": "Yahoo",
      "summary": "KeyBanc analyst Steve Barger raised the firm’s price target on Ametek (AME) to $215 from $205 and keeps an Overweight rating on the shares. The firm thinks Ametek has 200-400 basis points of margin expansion in its EMG segment, as the recent Paragon Medical acquisition continues to get integrated and segment margins return to mid-20s%. KeyBanc thinks 5% organic growth +3% of M&A with average incremental margins could lead to about $8.64 in EPS by FY27, implying a high single digit compound annua",
      "url": "https://finnhub.io/api/news?id=e638bc13f9ac81969c76f73ebd0db5dfc4e2a5998da6ab48841430b05c5be8ab"
    }
  }
]